<DOC>
	<DOCNO>NCT00401401</DOCNO>
	<brief_summary>The purpose study investigate safety zalutumumab combination chemotherapy radiotherapy treatment patient head neck cancer</brief_summary>
	<brief_title>Zalutumumab Combination With Chemotherapy Radiotherapy Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients locoregionally advance squamous cell carcinoma oral cavity , oropharynx , hypopharynx larynx Prior treatment radiotherapy head neck area Prior treatment chemotherapy Prior treatment similar drug ( e.g . EGFr antibody , EGFr inhibitor ) Previous surgery curative intent head neck cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>